(Reuters) U.S.-Israeli NeuroRx pharmaceutical company, partnered with Geneva-based Relief Therapeutics Holdings, has developed RLF-100, or aviptadil, a synthetic form of a natural peptide that protects the lung, for treating critically ill Covid-19 patients. Patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the U.S., the two drug companies said on Sunday. Similar results were seen in more than 15 patients treated under emergency use.
2020-08-03 00:00:00Full ArticleBACK Visit the Daily Alert Archive